Clinical laboratory · 2026
Novel Basophilic Crystals in Acute Myeloid Leukemia with EZH2/DNMT3A Mutations: Aggressive Case with Thrombosis.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zhiqing, He Dong, Wen Xinglin, Xu Song, Xiao Dejun
Аннотация
BACKGROUND: This study reports a novel case of EZH2/DNMT3A-mutated AML featuring unique basophilic rectangular crystals in blasts, associated with aggressive disease and thrombotic complications.
METHODS: A 56-year-old male underwent morphological analysis (light microscopy, cytochemistry), clinical monitoring, and molecular profiling.
RESULTS: MPO-negative rectangular crystals (3 - 20 µm) persisted despite therapy, demonstrating chemoresistance. These crystals were distinct from Auer rods and associated with an aggressive clinical course, including fatal DVT/PE within 7 months. Molecular analysis revealed EZH2/DNMT3A mutations, suggesting epigenetic dysregulation underlying both crystal formation and thrombotic predisposition.
CONCLUSIONS: This first-reported association between such crystals and EZH2/DNMT3A-mutated AML highlights their potential as high-risk markers. The findings implicate epigenetic dysregulation in treatment resistance and thrombogenesis, warranting cryo-EM studies to elucidate crystal composition and mechanisms. Clinically, this supports vigilant thromboprophylaxis and exploration of combined epigenetic/anticoagulant therapies for similar high-risk cases.
METHODS: A 56-year-old male underwent morphological analysis (light microscopy, cytochemistry), clinical monitoring, and molecular profiling.
RESULTS: MPO-negative rectangular crystals (3 - 20 µm) persisted despite therapy, demonstrating chemoresistance. These crystals were distinct from Auer rods and associated with an aggressive clinical course, including fatal DVT/PE within 7 months. Molecular analysis revealed EZH2/DNMT3A mutations, suggesting epigenetic dysregulation underlying both crystal formation and thrombotic predisposition.
CONCLUSIONS: This first-reported association between such crystals and EZH2/DNMT3A-mutated AML highlights their potential as high-risk markers. The findings implicate epigenetic dysregulation in treatment resistance and thrombogenesis, warranting cryo-EM studies to elucidate crystal composition and mechanisms. Clinically, this supports vigilant thromboprophylaxis and exploration of combined epigenetic/anticoagulant therapies for similar high-risk cases.